Get notified when PDSB files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Short Squeeze (new) — The company explicitly states it is currently the target of a short squeeze, a company-specific risk that could cause investors to lose a significant portion of their investment.
NASDAQ: PDSB PDS Biotechnology Corp 424B5

PDS Biotech launches up to $50M at-the-market offering at $1.05/share, with most proceeds repaying a 10% note

Filed June 15, 2026 · ~1 min read

Key Changes

  • high

    PDS Biotech is offering up to $50 million of common stock at $1.05 per share, the last reported sale price on June 12, 2026.

    The Offering verify on EDGAR →
  • high

    The company must use 100% of net proceeds to repay a 10% Promissory Note; only if proceeds exceed the next amortization payment can 40% of the excess be retained for working capital.

    Use of Proceeds verify on EDGAR →
  • high

    New investors face immediate dilution of about $0.62 per share, with net tangible book value rising from $0.07 to $0.52 per share.

    Dilution verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (IMMR 10-Q) is open in full — no account needed.

Partner

Trade PDSB commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify